Wearable ECGs and Atrial Fibrillation Detection in Australian Communities
Atrial fibrillation, often shortened to AF, is the most common cardiac arrhythmia encountered in clinical practice across Australia. It contributes to thousands of strokes every year, many of which could be prevented with timely diagnosis and anticoagulation. Yet a substantial proportion of people living with AF remain unaware of their condition because episodes are frequently brief, intermittent, or asymptomatic.
Wearable electrocardiogram devices have moved well beyond the traditional 24-hour Holter monitor that has dominated outpatient cardiac investigation for decades. Modern patch monitors, smart watches with ECG capability, and handheld single-lead recorders now allow prolonged monitoring in everyday settings. For patients in regional and remote parts of Queensland, where access to specialist cardiology services can require long travel, these devices offer a practical way to capture rhythm disturbances that might otherwise go unrecognised.
Queensland has become a hub for translational research that bridges the gap between bench science and bedside care. Networks that bring researchers, clinicians and health service providers together are essential for evaluating how digital tools perform outside controlled trial environments. Within this ecosystem, groups working through https://brisbanediamantina.com/ have prioritised studies that examine how continuous monitoring can be embedded into routine care for the people most likely to benefit.
This article explores the evidence supporting wearable ECG screening for atrial fibrillation in high-risk ambulatory populations, with a particular focus on the Australian context. It considers how these technologies might be deployed in primary care, aged care facilities, and rural outreach programs, and outlines practical considerations for clinicians, researchers, and health service planners.
The clinical burden of atrial fibrillation in Australia
More than half a million Australians are estimated to be living with atrial fibrillation, and prevalence rises sharply with age. The condition is associated with a five-fold increase in stroke risk, and AF-related strokes tend to be more severe and disabling than those from other causes. In Queensland, hospital admissions for stroke and transient ischaemic attacks place a considerable load on both metropolitan tertiary centres and smaller regional hospitals.
Indigenous Australians experience higher rates of cardiovascular disease and rheumatic heart disease, which can predispose to atrial arrhythmias. Programs that combine community-based screening with culturally appropriate follow-up are therefore particularly important in northern and western Queensland, where many patients live far from major cardiac services. The Royal Brisbane and Women's Hospital and the Princess Alexandra Hospital together manage a large share of complex arrhythmia care in the southeast corner of the state.
Cost is another pressing consideration. The Pharmaceutical Benefits Scheme subsidises anticoagulants for stroke prevention in AF, but the medication only helps those who have been diagnosed. Many strokes attributable to undiagnosed AF occur in people who have never had an ECG recorded outside a routine check-up. Closing that diagnostic gap is a strategic priority for the National Stroke Foundation and aligns with state-level plans for cardiovascular care.
How wearable ECG technology compares with traditional monitoring
Contemporary wearable ECG devices generally fall into three broad categories. Patch-based recorders are adhered to the chest and can continuously record a single-lead ECG for up to two weeks. Smart watch and wristband devices rely on optical photoplethysmography for initial detection, prompting the user to take a confirmatory single-lead ECG with a fingertip sensor. Handheld devices, some connected to smartphone apps, allow on-demand rhythm strips when symptoms occur. The underlying algorithms distinguish sinus rhythm from atrial fibrillation by analysing R-R interval irregularity and the absence of discrete P waves.
The standard 12-lead ECG remains the reference for diagnosing atrial fibrillation when the patient is in rhythm at the time of recording. A 24-hour Holter monitor extends that window but still misses paroxysmal episodes that occur intermittently. Wearable patch monitors and smart watch devices extend monitoring to days or weeks, dramatically increasing the diagnostic yield for paroxysmal AF.
A trade-off exists between the richness of the ECG signal and the duration of monitoring. Multi-lead patches provide better P wave visualisation, which can help differentiate AF from other supraventricular arrhythmias. Single-lead devices are more comfortable and acceptable for long-term wear, but they are less useful for detecting atrial flutter or for monitoring patients with bundle branch block. The Therapeutic Goods Administration classifies many of these products as medical devices, requiring manufacturers to meet specified standards for electrical safety, signal fidelity, and algorithm performance before marketing locally.
Targeting high-risk ambulatory populations
Certain groups stand to benefit most from extended ECG monitoring. Older adults living independently in the community often have multiple risk factors for AF, including hypertension, diabetes, and sleep apnoea. Post-stroke patients, even after a transient ischaemic attack, warrant investigation for paroxysmal arrhythmias that may have caused the event. Patients awaiting cardiac surgery or cardioversion require pre-procedure rhythm assessment to guide timing and anticoagulation.
In the Australian setting, aged care residents represent a particularly important target. Many have cognitive impairment and may not report palpitations, yet their stroke risk is high. A wearable patch applied for one to two weeks can identify undiagnosed AF in a significant proportion of residents, prompting a review of anticoagulation. Several Queensland Health pilots have explored this approach in collaboration with university partners across the state.
Another priority group includes adults with obesity, sleep disordered breathing, or metabolic syndrome, where AF incidence is rising in line with population trends. Workplace screening programs have also attracted interest, particularly for industries with safety-critical roles. Whatever the setting, the key is to couple any positive finding with appropriate clinical follow-up, including review by a GP or cardiologist and shared decision-making about long-term anticoagulation.
Evidence from Australian and international studies
Large randomised trials conducted overseas have shown that systematic screening for atrial fibrillation using intermittent ECG recordings can increase detection rates compared with usual care. The STROKESTOP study in Sweden and the LOOP study in Denmark both demonstrated higher AF detection with longer monitoring periods, though the impact on stroke reduction has been more modest than initially hoped. Local studies are now examining whether similar approaches are cost-effective within the Australian health funding environment.
Researchers at the University of Queensland and QIMR Berghofer Medical Research Institute have contributed data on AF epidemiology and risk prediction in Queensland cohorts. Their work has highlighted regional variation in AF prevalence and outcomes, with some rural communities experiencing higher rates of complications. Such findings support the case for targeted screening programs that focus resources where the yield is likely to be highest.
A growing body of evidence supports the use of smart watch-derived ECGs as a triage tool rather than a definitive diagnostic test. Most algorithms perform well in clean signal conditions, but real-world performance degrades with movement artefact and poor electrode contact. Australian clinicians have reported that consumer devices can play a useful role in flagging potential arrhythmias that warrant formal investigation, provided patients are counselled about appropriate interpretation.
Integration with primary care and telehealth
General practice sits at the centre of cardiovascular risk management in Australia, and any wearable ECG strategy must align with how GPs work day to day. Medicare Benefits Schedule items exist for ambulatory ECG monitoring and for prolonged implantable loop recorder follow-up, but reimbursement for consumer wearable devices remains limited. Sustainable models will need to address how device data is reviewed, who interprets positive findings, and how findings are integrated into the patient's medical record.
Telehealth offers a way to extend specialist cardiology expertise into regional areas. Queensland's telehealth network already supports remote consultations between rural hospitals and metropolitan tertiary centres. Wearable ECGs that transmit data securely to a clinical portal could be reviewed by a cardiologist based at a major Brisbane hospital, with findings relayed back to the referring GP and patient within days.
Education is a critical enabler. Practice nurses and allied health professionals can play a key role in fitting patch monitors, instructing patients on smart watch use, and triaging flagged events. Training programs delivered through Primary Health Networks across Queensland are well placed to upskill the workforce. Where English is a second language, or where patients prefer culturally appropriate care, bilingual health workers and Aboriginal and Torres Strait Islander health practitioners are invaluable partners.
Ethical, governance and data considerations
Wearable ECGs generate continuous streams of personal health data, raising important questions about privacy, consent, and data security. In Australia, the Privacy Act and the Australian Privacy Principles govern how health information is collected, stored, and shared. Cloud-based device platforms must demonstrate compliance with these requirements, and patients need clear information about how their data will be used.
Research ethics oversight remains essential, particularly when devices are deployed outside traditional clinical settings. The National Health and Medical Research Council framework for clinical trials and the state-level ethics committees require rigorous processes for obtaining informed consent, especially for people who may have cognitive impairment or who are dependent on others for care. Health services introducing new wearable monitoring programs should engage their ethics and governance committees early in the planning process.
Equity is a further concern. The cost of consumer wearable devices is not always affordable, and reliance on personal technology risks excluding those most at risk. Public health programs should consider loan devices or fully subsidised patch monitors for high-risk patients, ensuring that the benefits of AF detection are not limited to those who can afford a smart watch. Embedding monitoring within existing services, such as annual health assessments for people aged 75 and over, may offer a practical path forward.
Practical recommendations for clinicians and health services
- Identify high-risk ambulatory patients proactively, including those aged 65 and over with hypertension, diabetes, or prior stroke, and consider systematic screening during routine consultations.
- Choose devices with documented Australian Register of Therapeutic Goods approval, and verify the performance of their detection algorithms in peer-reviewed validation studies.
- Use a stepped monitoring approach that combines a baseline 12-lead ECG, an extended patch monitor where indicated, and patient-triggered recordings for symptomatic episodes.
- Establish clear local pathways for review of flagged events, with timely access to cardiology input through telehealth or outreach clinics where specialist care is not locally available.
- Engage practice nurses, Aboriginal and Torres Strait Islander health workers, and bilingual educators to support patient understanding and follow-up, particularly in regional and culturally diverse communities.
Health services, research institutes and policymakers across Queensland have a shared opportunity to lead the careful introduction of wearable ECG screening for atrial fibrillation in high-risk ambulatory populations. By combining robust technology assessment, equitable access, and integration with primary care, Australia can turn continuous rhythm monitoring from a consumer novelty into a public health tool. Collaborative networks that connect researchers, clinicians and patients will be central to making this vision a reality, and Queensland-based collaborations are well positioned to drive the work forward.
